Biogen
NEWS
Johnson & Johnson’s Janssen division has decided to end its trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
As Biogen turns 40 years old, some biotech insiders and analysts seem to be concerned that the Boston-based pharmaceutical company has too many eggs in one developmental basket.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
Shares of Ionis Pharmaceuticals are up more than 10 percent in premarket trading after Biogen handed over $1 billion to support a new 10-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
JOBS
IN THE PRESS